Response to infliximab is related to disease duration in paediatric Crohn's disease

P. Lionetti, F. Bronzini, C. Salvestrini, C. Bascietto, R. Berni Canani, G. L. Dé Angelis, G. Guariso, S. Martelossi, B. Papadatou, A. Barabino

Research output: Contribution to journalArticle

139 Citations (Scopus)

Abstract

Background: Infliximab is an effective therapy in adult patients with refractory and fistulizing Crohn's disease. Experience in children is still limited. Aim: To evaluate the experience in 22 children and adolescents treated with infliximab with refractory and/or fistulizing Crohn's disease, and to compare duration of response in children between early Crohn's disease and late Crohn's disease. Methods: The experience in 22 children and adolescents treated with a total of 73 infusions was evaluated retrospectively. Treatment indication was refractory Crohn's disease in 9/22 patients, fistulizing Crohn's disease in 7/22 patients and both these conditions in 6/22. All patients with refractory Crohn's disease had late Crohn's disease (> 1 year), whereas 6/13 patients with fistulas had early disease (<1 year). Results: Mean Paediatric Crohn's Disease Activity Index (PCDAI) decreased from 41.2 to 16.2 at 4 weeks (P <0.01), and to 15.4 at 18 weeks (P <0.01). Mean PCDAI at 18 weeks in children with early Crohn's disease and late Crohn's disease was 5. 5 and 18.1, respectively (P <0.05). Complete closure of fistulas was obtained in 5/6 children with early Crohn's disease and in 2/7 children with late Crohn's disease. Immediate adverse reactions were observed in two children. Conclusions: Infliximab is a highly effective treatment in children and adolescents with both severe refractory or fistulizing Crohn's disease. Children with early Crohn's disease have a higher chance of prolonged response to infliximab than children with late Crohn's disease.

Original languageEnglish
Pages (from-to)425-431
Number of pages7
JournalAlimentary Pharmacology and Therapeutics
Volume18
Issue number4
DOIs
Publication statusPublished - Aug 15 2003

Fingerprint

Crohn Disease
Pediatric Crohn's disease
Infliximab
Fistula
Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Response to infliximab is related to disease duration in paediatric Crohn's disease. / Lionetti, P.; Bronzini, F.; Salvestrini, C.; Bascietto, C.; Berni Canani, R.; Dé Angelis, G. L.; Guariso, G.; Martelossi, S.; Papadatou, B.; Barabino, A.

In: Alimentary Pharmacology and Therapeutics, Vol. 18, No. 4, 15.08.2003, p. 425-431.

Research output: Contribution to journalArticle

Lionetti, P, Bronzini, F, Salvestrini, C, Bascietto, C, Berni Canani, R, Dé Angelis, GL, Guariso, G, Martelossi, S, Papadatou, B & Barabino, A 2003, 'Response to infliximab is related to disease duration in paediatric Crohn's disease', Alimentary Pharmacology and Therapeutics, vol. 18, no. 4, pp. 425-431. https://doi.org/10.1046/j.1365-2036.2003.01672.x
Lionetti P, Bronzini F, Salvestrini C, Bascietto C, Berni Canani R, Dé Angelis GL et al. Response to infliximab is related to disease duration in paediatric Crohn's disease. Alimentary Pharmacology and Therapeutics. 2003 Aug 15;18(4):425-431. https://doi.org/10.1046/j.1365-2036.2003.01672.x
Lionetti, P. ; Bronzini, F. ; Salvestrini, C. ; Bascietto, C. ; Berni Canani, R. ; Dé Angelis, G. L. ; Guariso, G. ; Martelossi, S. ; Papadatou, B. ; Barabino, A. / Response to infliximab is related to disease duration in paediatric Crohn's disease. In: Alimentary Pharmacology and Therapeutics. 2003 ; Vol. 18, No. 4. pp. 425-431.
@article{bcb9799f67eb4e51b18470264e34ad30,
title = "Response to infliximab is related to disease duration in paediatric Crohn's disease",
abstract = "Background: Infliximab is an effective therapy in adult patients with refractory and fistulizing Crohn's disease. Experience in children is still limited. Aim: To evaluate the experience in 22 children and adolescents treated with infliximab with refractory and/or fistulizing Crohn's disease, and to compare duration of response in children between early Crohn's disease and late Crohn's disease. Methods: The experience in 22 children and adolescents treated with a total of 73 infusions was evaluated retrospectively. Treatment indication was refractory Crohn's disease in 9/22 patients, fistulizing Crohn's disease in 7/22 patients and both these conditions in 6/22. All patients with refractory Crohn's disease had late Crohn's disease (> 1 year), whereas 6/13 patients with fistulas had early disease (<1 year). Results: Mean Paediatric Crohn's Disease Activity Index (PCDAI) decreased from 41.2 to 16.2 at 4 weeks (P <0.01), and to 15.4 at 18 weeks (P <0.01). Mean PCDAI at 18 weeks in children with early Crohn's disease and late Crohn's disease was 5. 5 and 18.1, respectively (P <0.05). Complete closure of fistulas was obtained in 5/6 children with early Crohn's disease and in 2/7 children with late Crohn's disease. Immediate adverse reactions were observed in two children. Conclusions: Infliximab is a highly effective treatment in children and adolescents with both severe refractory or fistulizing Crohn's disease. Children with early Crohn's disease have a higher chance of prolonged response to infliximab than children with late Crohn's disease.",
author = "P. Lionetti and F. Bronzini and C. Salvestrini and C. Bascietto and {Berni Canani}, R. and {D{\'e} Angelis}, {G. L.} and G. Guariso and S. Martelossi and B. Papadatou and A. Barabino",
year = "2003",
month = "8",
day = "15",
doi = "10.1046/j.1365-2036.2003.01672.x",
language = "English",
volume = "18",
pages = "425--431",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "4",

}

TY - JOUR

T1 - Response to infliximab is related to disease duration in paediatric Crohn's disease

AU - Lionetti, P.

AU - Bronzini, F.

AU - Salvestrini, C.

AU - Bascietto, C.

AU - Berni Canani, R.

AU - Dé Angelis, G. L.

AU - Guariso, G.

AU - Martelossi, S.

AU - Papadatou, B.

AU - Barabino, A.

PY - 2003/8/15

Y1 - 2003/8/15

N2 - Background: Infliximab is an effective therapy in adult patients with refractory and fistulizing Crohn's disease. Experience in children is still limited. Aim: To evaluate the experience in 22 children and adolescents treated with infliximab with refractory and/or fistulizing Crohn's disease, and to compare duration of response in children between early Crohn's disease and late Crohn's disease. Methods: The experience in 22 children and adolescents treated with a total of 73 infusions was evaluated retrospectively. Treatment indication was refractory Crohn's disease in 9/22 patients, fistulizing Crohn's disease in 7/22 patients and both these conditions in 6/22. All patients with refractory Crohn's disease had late Crohn's disease (> 1 year), whereas 6/13 patients with fistulas had early disease (<1 year). Results: Mean Paediatric Crohn's Disease Activity Index (PCDAI) decreased from 41.2 to 16.2 at 4 weeks (P <0.01), and to 15.4 at 18 weeks (P <0.01). Mean PCDAI at 18 weeks in children with early Crohn's disease and late Crohn's disease was 5. 5 and 18.1, respectively (P <0.05). Complete closure of fistulas was obtained in 5/6 children with early Crohn's disease and in 2/7 children with late Crohn's disease. Immediate adverse reactions were observed in two children. Conclusions: Infliximab is a highly effective treatment in children and adolescents with both severe refractory or fistulizing Crohn's disease. Children with early Crohn's disease have a higher chance of prolonged response to infliximab than children with late Crohn's disease.

AB - Background: Infliximab is an effective therapy in adult patients with refractory and fistulizing Crohn's disease. Experience in children is still limited. Aim: To evaluate the experience in 22 children and adolescents treated with infliximab with refractory and/or fistulizing Crohn's disease, and to compare duration of response in children between early Crohn's disease and late Crohn's disease. Methods: The experience in 22 children and adolescents treated with a total of 73 infusions was evaluated retrospectively. Treatment indication was refractory Crohn's disease in 9/22 patients, fistulizing Crohn's disease in 7/22 patients and both these conditions in 6/22. All patients with refractory Crohn's disease had late Crohn's disease (> 1 year), whereas 6/13 patients with fistulas had early disease (<1 year). Results: Mean Paediatric Crohn's Disease Activity Index (PCDAI) decreased from 41.2 to 16.2 at 4 weeks (P <0.01), and to 15.4 at 18 weeks (P <0.01). Mean PCDAI at 18 weeks in children with early Crohn's disease and late Crohn's disease was 5. 5 and 18.1, respectively (P <0.05). Complete closure of fistulas was obtained in 5/6 children with early Crohn's disease and in 2/7 children with late Crohn's disease. Immediate adverse reactions were observed in two children. Conclusions: Infliximab is a highly effective treatment in children and adolescents with both severe refractory or fistulizing Crohn's disease. Children with early Crohn's disease have a higher chance of prolonged response to infliximab than children with late Crohn's disease.

UR - http://www.scopus.com/inward/record.url?scp=0042329252&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042329252&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2036.2003.01672.x

DO - 10.1046/j.1365-2036.2003.01672.x

M3 - Article

VL - 18

SP - 425

EP - 431

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 4

ER -